<DOC>
	<DOCNO>NCT00973960</DOCNO>
	<brief_summary>The main objective study demonstrate safety efficacy EndoBarrier Flow Restrictor glycemic control diabetes subject Type 2 diabetes . The primary efficacy endpoint assessment glycemic control week 24 last assessment measure via HbA1c .</brief_summary>
	<brief_title>A Pilot Trial EndoBarrier™ Flow Restrictor Glycemic Improvement Type 2 Diabetics</brief_title>
	<detailed_description />
	<criteria>Age &gt; 18 year &lt; 55 year Male Female BMI &gt; 30 BMI &lt; 60 Subjects HbA1c &gt; 7.5 ≤ 10.0 % Subjects Type 2 diabetes treat ≤10 year Subjects Metformin and/or Sulfonylurea History failure nonsurgical weight loss method Subjects willing comply trial requirement Subjects sign informed consent form Women postmenopausal , surgically sterile oral contraceptive plan become pregnant course trial . Treatment represent unreasonable risk subject Subjects oral diabetic medication Metformin Sulfonylurea Subjects insulin Subjects diagnose Type 1 Diabetes Mellitus history ketoacidosis Subjects past medical history hypoglycemia Subjects abnormal gastric empty baseline , define &lt; 90 % stomach empty 4 hour Subjects weight loss &gt; 4.5 Kg ( 10 lb ) within 12 Weeks screening Subjects take corticosteroid drug know affect GI motility ( i.e . Reglan ) Pregnant intention become pregnant duration trial Unresolved alcohol drug addiction Subjects receive weight loss medication ( prescription , overthecounter , herbal dietary medication ) Previous gastrointestinal surgery could affect ability place EndoBarrier Flow Restrictor function implant . Subjects active uncontrolled GERD Subjects symptomatic kidney stone prior implant Subjects iron deficiency and/or iron deficiency anemia History Inflammatory bowel disease condition gastrointestinal tract , ulcer Crohn 's disease Subjects symptomatic gallstone prior implant Symptomatic coronary artery disease pulmonary dysfunction Known infection ( Subjects know infection time screen enrolled infection treat prior procedure ; still infection day procedure must withdraw ) History congenital acquire anomaly gastrointestinal tract atresias stenosis Pancreatitis serious organic condition Subjects require prescription anticoagulation therapy Subjects unable discontinue NSAIDs ( nonsteroidal antiinflammatory drug ) implant period Subject Family history know diagnosis preexist symptom systemic lupus erythematosus , scleroderma autoimmune connective tissue disorder Participating another ongoing investigational clinical trial Mentally retard emotionally unstable , exhibit psychological characteristic require medication affect appetite ( i.e . tricyclic antidepressant atypical antipsychotic medication ) , opinion Investigator , make subject poor candidate device placement clinical trial . Subjects active H. pylorus ( Note : Subjects may enrol prior history H. Pylori successfully treat diagnosed baseline test undergo successful treatment procedure ) Subjects history coagulopathy , upper gastrointestinal bleeding condition esophageal gastric varix , congenital acquire intestinal telangiectasia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2011</verification_date>
</DOC>